公开(公告)号：US20150344926A1

公开(公告)日：2015-12-03

申请号：US14430731

申请日：2013-09-26

申请人： CONTIPRO BIOTECH S.R.O.

发明人： Lenka Knorova ,  Dzianis Smirnou ,  Veronika Leierova ,  Martin Krcmar ,  Lukas Franke ,  Vladimir Velebny

IPC分类号： C12P19/26 ,  C12N9/88

CPC分类号： C12P19/26 ,  C12N9/88 ,  C12P19/04 ,  C12P19/12 ,  C12Y402/02001

摘要： The invention relates to an enzyme which is able to degrade hyaluronic acid and which is produced by fungi of the genus Fistulina (especially Fistulina hepatica). The degradation proceeds by lyase mechanism in which double bonds between C4 and C5 of glucuronic acid are formed. The invention also includes the process of preparation and purification of the enzyme and a possible practical use thereof for the preparation of low-molecular hyaluronan or of cosmetic or pharmaceutical devices. Further, the invention relates to the method of preparation of low-molecular hyaluronan.

摘要翻译： 本发明涉及一种能够降解透明质酸并由瘘管真菌（特别是肝瘘）产生的酶。 通过裂解酶机理进行降解，其中形成葡萄糖醛酸的C4和C5之间的双键。 本发明还包括酶的制备和纯化方法及其可用于制备低分子透明质酸或化妆品或药物装置的实际应用。 此外，本发明涉及低分子透明质酸的制备方法。

公开(公告)号：US20090028829A1

公开(公告)日：2009-01-29

申请号：US10848564

申请日：2004-05-17

申请人： Elliott A. Gruskin ,  Anthony O. Caggiano ,  Gargi Roy ,  Jennifer Iaci ,  Michael P. Zimber

发明人： Elliott A. Gruskin ,  Anthony O. Caggiano ,  Gargi Roy ,  Jennifer Iaci ,  Michael P. Zimber

IPC分类号： A61K35/12 ,  A61K38/47 ,  A61K38/02 ,  A61P25/00

CPC分类号： C12N9/88 ,  A61K35/30 ,  A61K38/00 ,  A61K38/51 ,  A61K45/06 ,  C07K14/005 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/10 ,  C12N9/2408 ,  C12Y302/01035 ,  C12Y302/01036 ,  C12Y402/02001 ,  C12Y402/02004 ,  C12Y402/02005

摘要： This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

摘要翻译： 本公开涉及能够用于治疗脊髓损伤和中枢神经系统（CNS）的相关病症的组合物，特别是包括蛋白多糖降解分子和能够阻断和/或超过神经元活性的组合物的组合物 生长抑制分子，以及融合蛋白，其包括蛋白聚糖降解结构域和能够阻断和或超过神经元生长抑制分子活性的结构域。

公开(公告)号：US20060233782A1

公开(公告)日：2006-10-19

申请号：US10848561

申请日：2004-05-17

申请人： Elliott Gruskin ,  Rohini D'Souza ,  Gargi Roy ,  Anthony Caggiano

发明人： Elliott Gruskin ,  Rohini D'Souza ,  Gargi Roy ,  Anthony Caggiano

IPC分类号： A61K38/47 ,  A61K35/30 ,  C07H21/04 ,  C12P21/06 ,  C12N9/24 ,  C12N15/06

CPC分类号： C12N9/88 ,  A61K35/30 ,  A61K38/00 ,  A61K38/51 ,  A61K45/06 ,  C07K14/005 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/10 ,  C12N9/2408 ,  C12Y302/01035 ,  C12Y302/01036 ,  C12Y402/02001 ,  C12Y402/02004 ,  C12Y402/02005

摘要： The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

摘要翻译： 本公开涉及软骨素酶蛋白的制备和缺失突变体及其在促进治疗组合物扩散到组织中的方法及其在中枢神经系统（“CNS”）损伤或疾病之后神经功能恢复的用途。

公开(公告)号：US20190194264A1

公开(公告)日：2019-06-27

申请号：US16319835

申请日：2017-08-11

申请人： UNIVERSITÉ DE NAMUR

发明人： Frédéric André Lauber ,  Francesco Renzi ,  Guy Richard Comelis

IPC分类号： C07K14/195 ,  C12P21/02

CPC分类号： C07K14/195 ,  C07K2319/035 ,  C12P21/02 ,  C12Y302/01018 ,  C12Y402/02001

摘要： Described herein are polypeptides comprising a lipoprotein export signal, polypeptide precursors comprising a lipoprotein export signal, nucleic acids encoding said polypeptides or polypeptide precursors, recombinant expression vectors comprising nucleic acids encoding said lipoprotein export signal and/or polypeptides or polypeptide precursors, and 5 recombinant host cells comprising these vectors. The application further provides uses of these polypeptides, polypeptide precursors, nucleic acids, recombinant expression vectors and recombinant host cells.

公开(公告)号：US20170151307A1

公开(公告)日：2017-06-01

申请号：US15309177

申请日：2015-05-07

申请人： Applied Molecular Transport LLC

发明人： Randall J Mrsny ,  Tahir Mahmood

IPC分类号： A61K38/16 ,  A61K38/27 ,  A61K38/20

CPC分类号： A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001

摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

公开(公告)号：US20160361437A1

公开(公告)日：2016-12-15

申请号：US15121283

申请日：2015-02-24

申请人： The University of Manchester

发明人： Robert Lucas ,  Paul Bishop ,  Jasmina Cehajic-Kapetanovic

IPC分类号： A61K48/00 ,  A61K31/137 ,  A61K9/00 ,  A61K31/4409 ,  A61K38/17 ,  A61K38/51

CPC分类号： A61K48/005 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/137 ,  A61K31/4409 ,  A61K31/7088 ,  A61K38/1709 ,  A61K38/51 ,  A61K48/0058 ,  A61K48/0075 ,  A61K48/0083 ,  C07K14/723 ,  C12N9/88 ,  C12N2750/14143 ,  C12N2830/008 ,  C12Y402/02001 ,  C12Y402/02008 ,  A61K2300/00

摘要： The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.

摘要翻译： 本发明涉及向细胞提供光感受器功能的改进方法，例如用于治疗视网膜变性。 本发明还涉及组合物和试剂盒，特别是用于这些方法。

公开(公告)号：US07968089B2

公开(公告)日：2011-06-28

申请号：US12167573

申请日：2008-07-03

申请人： Elliott A. Gruskin ,  Anthony O. Caggiano ,  Gargi Roy ,  Rohini D'Souza

发明人： Elliott A. Gruskin ,  Anthony O. Caggiano ,  Gargi Roy ,  Rohini D'Souza

IPC分类号： A61K38/51 ,  C12N15/60 ,  C12N9/88

CPC分类号： C12N9/88 ,  A61K35/30 ,  A61K38/00 ,  A61K38/51 ,  A61K45/06 ,  C07K14/005 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/10 ,  C12N9/2408 ,  C12Y302/01035 ,  C12Y302/01036 ,  C12Y402/02001 ,  C12Y402/02004 ,  C12Y402/02005

摘要： The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

摘要翻译： 本公开涉及软骨素酶蛋白的制备和缺失突变体及其在促进治疗组合物扩散到组织中的方法及其在中枢神经系统（“CNS”）损伤或疾病之后神经功能恢复的用途。

公开(公告)号：US20090041728A1

公开(公告)日：2009-02-12

申请号：US12167573

申请日：2008-07-03

申请人： Elliott A. Gruskin ,  Rohini D'Souza ,  Gargi Roy ,  Anthony O. Caggiano

发明人： Elliott A. Gruskin ,  Rohini D'Souza ,  Gargi Roy ,  Anthony O. Caggiano

IPC分类号： A61K35/74 ,  A61K38/16 ,  A61P25/00

CPC分类号： C12N9/88 ,  A61K35/30 ,  A61K38/00 ,  A61K38/51 ,  A61K45/06 ,  C07K14/005 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/10 ,  C12N9/2408 ,  C12Y302/01035 ,  C12Y302/01036 ,  C12Y402/02001 ,  C12Y402/02004 ,  C12Y402/02005

摘要： The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

摘要翻译： 本公开涉及软骨素酶蛋白的制备和缺失突变体及其在促进治疗组合物扩散到组织中的方法及其在中枢神经系统（“CNS”）损伤或疾病之后神经功能恢复的用途。

公开(公告)号：US20240207372A1

公开(公告)日：2024-06-27

申请号：US18361724

申请日：2023-07-28

申请人： Thornhill Therapeutics, Inc.

发明人： Randall J. Mrsny ,  Tahir Mahmood

IPC分类号： A61K38/45 ,  A61K38/16 ,  A61K38/17 ,  A61K38/20 ,  A61K38/26 ,  A61K38/27 ,  A61K38/48 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/54 ,  C07K16/24

CPC分类号： A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90

摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.

公开(公告)号：US20180073007A9

公开(公告)日：2018-03-15

申请号：US14535113

申请日：2014-11-06

申请人： ACORDA THERAPEUTICS, INC.

发明人： Elliott A. GRUSKIN ,  Anthony O. CAGGIANO ,  Gargi ROY ,  Jennifer IACI ,  Michael P. ZIMBER

IPC分类号： C12N9/88 ,  A61K38/51 ,  A61K35/30

CPC分类号： C12N9/88 ,  A61K35/30 ,  A61K38/00 ,  A61K38/51 ,  A61K45/06 ,  C07K14/005 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/10 ,  C12N9/2408 ,  C12Y302/01035 ,  C12Y302/01036 ,  C12Y402/02001 ,  C12Y402/02004 ,  C12Y402/02005

摘要： This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.